Matches in SemOpenAlex for { <https://semopenalex.org/work/W2068040028> ?p ?o ?g. }
Showing items 1 to 71 of
71
with 100 items per page.
- W2068040028 endingPage "A550" @default.
- W2068040028 startingPage "A550" @default.
- W2068040028 abstract "Budget impact models (BIMs) which demonstrate the economic impact of introducing or increasing the use of specific treatments are routinely used to assist the NHS with financial planning. A core component of any BIM is the estimation of the eligible patient population. The objective of this study was to identify an appropriate methodology for estimating the size of the stage IIIb/IV EGFR M+ non-small cell lung cancer (NSCLC) patient population eligible for first-line treatment with a tyrosine kinase inhibitor such as afatinib (GIOTRIF®). A review of the approach taken by NICE in the costing statements of all treatment options for patients with advanced (stage IIIb) or metastatic (stage IV) EGFR M+ NSCLC was conducted. The costing statements of tyrosine kinase inhibitors afatinib, erlotinib and gefitinib were reviewed, as was the costing statement for the chemotherapy agent pemetrexed. Based on the reviewed approaches, the calculation can be broken down into six discrete steps from the estimation of the general population to the target population: (1) Incidence of lung cancer; (2) Proportion of NSCLC; (3) Proportion with stage IIIb/IV NSCLC; (4) Proportion who receive first-line chemotherapy; (5) Proportion with EGFR mutation status; and (6) Proportion who are EGFR M+. A detailed breakdown of the methods used to calculate the patient population eligible for treatment with afatinib was not available in the respective NICE costing statement; however the eligible population estimated by NICE validates that this approach is reasonable. The methodology employed by NICE to estimate the proportion of stage IIIb/IV EGFR M+ NSCLC patients was broadly consistent across all costing statements considered. Is it reasonable to assume that this approach, used to estimate the population of stage IIIb/IV EGFR M+ NSCLC patients in England and Wales is also applicable in Scotland and Ireland." @default.
- W2068040028 created "2016-06-24" @default.
- W2068040028 creator A5016545628 @default.
- W2068040028 date "2014-11-01" @default.
- W2068040028 modified "2023-09-27" @default.
- W2068040028 title "A Methodology for Estimating the Population of Advanced or Metastatic EGFR M+ Non-Small Cell Lung Cancer Patients in the UK and Ireland" @default.
- W2068040028 doi "https://doi.org/10.1016/j.jval.2014.08.1794" @default.
- W2068040028 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27201791" @default.
- W2068040028 hasPublicationYear "2014" @default.
- W2068040028 type Work @default.
- W2068040028 sameAs 2068040028 @default.
- W2068040028 citedByCount "0" @default.
- W2068040028 crossrefType "journal-article" @default.
- W2068040028 hasAuthorship W2068040028A5016545628 @default.
- W2068040028 hasBestOaLocation W20680400281 @default.
- W2068040028 hasConcept C121608353 @default.
- W2068040028 hasConcept C126322002 @default.
- W2068040028 hasConcept C143998085 @default.
- W2068040028 hasConcept C199360897 @default.
- W2068040028 hasConcept C2776256026 @default.
- W2068040028 hasConcept C2776694085 @default.
- W2068040028 hasConcept C2777240266 @default.
- W2068040028 hasConcept C2778087573 @default.
- W2068040028 hasConcept C2778239845 @default.
- W2068040028 hasConcept C2779256446 @default.
- W2068040028 hasConcept C2779438470 @default.
- W2068040028 hasConcept C2780580887 @default.
- W2068040028 hasConcept C2780586478 @default.
- W2068040028 hasConcept C2908647359 @default.
- W2068040028 hasConcept C41008148 @default.
- W2068040028 hasConcept C71924100 @default.
- W2068040028 hasConcept C99454951 @default.
- W2068040028 hasConceptScore W2068040028C121608353 @default.
- W2068040028 hasConceptScore W2068040028C126322002 @default.
- W2068040028 hasConceptScore W2068040028C143998085 @default.
- W2068040028 hasConceptScore W2068040028C199360897 @default.
- W2068040028 hasConceptScore W2068040028C2776256026 @default.
- W2068040028 hasConceptScore W2068040028C2776694085 @default.
- W2068040028 hasConceptScore W2068040028C2777240266 @default.
- W2068040028 hasConceptScore W2068040028C2778087573 @default.
- W2068040028 hasConceptScore W2068040028C2778239845 @default.
- W2068040028 hasConceptScore W2068040028C2779256446 @default.
- W2068040028 hasConceptScore W2068040028C2779438470 @default.
- W2068040028 hasConceptScore W2068040028C2780580887 @default.
- W2068040028 hasConceptScore W2068040028C2780586478 @default.
- W2068040028 hasConceptScore W2068040028C2908647359 @default.
- W2068040028 hasConceptScore W2068040028C41008148 @default.
- W2068040028 hasConceptScore W2068040028C71924100 @default.
- W2068040028 hasConceptScore W2068040028C99454951 @default.
- W2068040028 hasIssue "7" @default.
- W2068040028 hasLocation W20680400281 @default.
- W2068040028 hasLocation W20680400282 @default.
- W2068040028 hasOpenAccess W2068040028 @default.
- W2068040028 hasPrimaryLocation W20680400281 @default.
- W2068040028 hasRelatedWork W1994508061 @default.
- W2068040028 hasRelatedWork W2408182535 @default.
- W2068040028 hasRelatedWork W2476223812 @default.
- W2068040028 hasRelatedWork W2549473871 @default.
- W2068040028 hasRelatedWork W2822334320 @default.
- W2068040028 hasRelatedWork W2888534976 @default.
- W2068040028 hasRelatedWork W2979271184 @default.
- W2068040028 hasRelatedWork W4281670385 @default.
- W2068040028 hasRelatedWork W4307234767 @default.
- W2068040028 hasRelatedWork W2753213968 @default.
- W2068040028 hasVolume "17" @default.
- W2068040028 isParatext "false" @default.
- W2068040028 isRetracted "false" @default.
- W2068040028 magId "2068040028" @default.
- W2068040028 workType "article" @default.